BACKGROUND: Dasatinib, an inhibitor of Src-family kinases, combined with docetaxel in men with castrate-resistant prostate cancer (CRPC), affects bone turnover markers in a phase I/II clinical trial in metastatic CRPC. Only a subset of men benefit from this therapy, and predictive markers are lacking. We hypothesized a role for insulin-like growth factor-1 (IGF-1) as a predictive marker, since IGF-1 is important in both prostate cancer progression and bone development. Hence, we determined the association of IGF-1 expression to treatment response, and whether this expression resulted from tumor cells, the microenvironment, or their interactions. METHODS: We measured serum IGF-1 levels in men with CRPC treated with dasatinib plus docetaxel. To investigate the source of IGF-1, we utilized two different mouse models harboring human prostate cancer cells, and used species-specific IGF-1 ELISA kits (mouse vs. human). RESULTS: In men with CRPC, an increase in IGF-1 levels after one cycle of treatment with dasatinib and docetaxel is associated with a higher response rate and longer duration of treatment. Xenograft experiments with subcutaneous and intratibial injection of prostate cancer cells suggest that direct interaction of prostate cancer cells with bone microenvironment is necessary for IGF-1 induction, is entirely host-derived, and occurs only in mice that respond to dasatinib-based therapy. CONCLUSION: Our results support a role for serum IGF-1 as a potential biomarker for benefit from dasatinib-based combination treatments in CRPC.
BACKGROUND:Dasatinib, an inhibitor of Src-family kinases, combined with docetaxel in men with castrate-resistant prostate cancer (CRPC), affects bone turnover markers in a phase I/II clinical trial in metastatic CRPC. Only a subset of men benefit from this therapy, and predictive markers are lacking. We hypothesized a role for insulin-like growth factor-1 (IGF-1) as a predictive marker, since IGF-1 is important in both prostate cancer progression and bone development. Hence, we determined the association of IGF-1 expression to treatment response, and whether this expression resulted from tumor cells, the microenvironment, or their interactions. METHODS: We measured serum IGF-1 levels in men with CRPC treated with dasatinib plus docetaxel. To investigate the source of IGF-1, we utilized two different mouse models harboring humanprostate cancer cells, and used species-specific IGF-1 ELISA kits (mouse vs. human). RESULTS: In men with CRPC, an increase in IGF-1 levels after one cycle of treatment with dasatinib and docetaxel is associated with a higher response rate and longer duration of treatment. Xenograft experiments with subcutaneous and intratibial injection of prostate cancer cells suggest that direct interaction of prostate cancer cells with bone microenvironment is necessary for IGF-1 induction, is entirely host-derived, and occurs only in mice that respond to dasatinib-based therapy. CONCLUSION: Our results support a role for serum IGF-1 as a potential biomarker for benefit from dasatinib-based combination treatments in CRPC.
Authors: J M Chan; M J Stampfer; E Giovannucci; P H Gann; J Ma; P Wilkinson; C H Hennekens; M Pollak Journal: Science Date: 1998-01-23 Impact factor: 47.728
Authors: John C Araujo; Paul Mathew; Andrew J Armstrong; Edward L Braud; Edwin Posadas; Mathew Lonberg; Gary E Gallick; Géralyn C Trudel; Prashni Paliwal; Shruti Agrawal; Christopher J Logothetis Journal: Cancer Date: 2011-07-25 Impact factor: 6.860
Authors: June M Chan; Meir J Stampfer; Jing Ma; Peter Gann; J Michael Gaziano; Michael Pollak; Edward Giovannucci Journal: J Natl Cancer Inst Date: 2002-07-17 Impact factor: 13.506
Authors: Stephen R Plymate; Marie K Tennant; Stephen H Culp; Lillie Woodke; Marco Marcelli; Ilsa Colman; Peter S Nelson; Julie M Carroll; Charles T Roberts; Joy L Ware Journal: Prostate Date: 2004-11-01 Impact factor: 4.104
Authors: Justin Q Wang; Austin DeChalus; Devin N Chatterjee; Evan T Keller; Atsushi Mizokami; Giovanni Camussi; Andrew R Mendelsohn; Joseph F Renzulli Ii; Peter J Quesenberry; Devasis Chatterjee Journal: Crit Rev Oncog Date: 2015
Authors: Andreas Varkaris; Anastasia D Katsiampoura; John C Araujo; Gary E Gallick; Paul G Corn Journal: Cancer Metastasis Rev Date: 2014-09 Impact factor: 9.264